Company profile
Oncology Pharma Inc.
OTC: ONPH · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH 47DQ —GM —SS 42
v0.1 · 35/100 weight · pillars only
↑ listing tenure, return on assets · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$5.8k
Employees
1
as of 2026-08-25
Market cap
$1.4M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$5.8k-$5.8k2025
Operating income-$5.8k-$5.8k2025
Total assets$2.1M$2.1M2021
Liabilities$875.5k$875.5k2021
Equity$1.2M$1.2M2021
Revenue trend
FY2002 – FY2025 · USD
FY02
FY03
FY04
FY18
FY19
FY20
FY21
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oncology Pharma Inc.’s revenue?
Oncology Pharma Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Acro Biomedical Co., Ltd.17DCity View Green Holdings Inc.——Anything Technologies Media, Inc.32DAethlon Medical, Inc.42DBurzynski Research Institute, Inc.——The Cannaisseur Group, Inc.8DNeighbors
San Francisco →Key facts
CEOGeorge Malesek
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Francisco, CA
ExchangeOTC: ONPH
Employees1
IPO date1994-10-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.